cabozantinib,atezolizumab
exelixis,roche
['atezolizumab', 'blcsm', 'cabozantinib', 'urothelial', 'cosmic-021']
cabozantinib/atezolizumab showed encouraging clinical activity w/ manageable toxicities in certain patients w/ #urothelialcarcinoma, according to data from 3 cohorts of the cosmic-021 trial #asco22 #blcsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse.